Skip to main content

Branded

  • Avalere: Rising coinsurance means less certainty on cost for Medicare PDP beneficiaries
    WASHINGTON — Medicare Part D plan (PDP) beneficiaries might be paying more out of pocket for a majority of their prescription medication, according to a new analysis from Avalere Health. The company found that a majority — 58% of covered drugs among PDPs — of medications are subject to coinsurance rather than copayments for beneficiaries. In 2014, only about 35% of covered drugs were subject to coinsurance. 
     

  • Walgreens Flu Index heat map indicates high flu incidence across America
    DEERFIELD, Ill. - This week's Walgreens Flu Index report for the week of March 6 indicated Arizona, Mississippi and Texas were the top three states experiencing the highest incidences of influenza across the country. And while Mississippi topped the list in greatest flu activity gains as well, flu incidence appears to be gaining significantly in Kentucky and Hawaai as well. 
     
    For the week of March 6, the top 10 markets with flu activity were: 
     
    1. El Paso, Texas (Las Cruces, N.M.);

  • GlobalData: Big tobacco may manufacture next flu shot
    LONDON - A new tobacco-based seasonal influenza vaccine being developed by Mitsubishi Tanabe Pharma and currently in Phase III studies could potentially rival traditional chicken egg-based vaccines, as it aims to launch in the U.S. for the 2018-19 flu season, according to an analyst with research and consulting firm GlobalData.
     

  • FDA, Amarin reach settlement on off-label use promotion
    NEW YORK — Amarin announced Wednesday that New York’s Southern District Court had approved its proposed settlement with the Food and Drug Administration, reached Tuesday, over the promotion of off-label use for its Vascepa (icosapent ethyl) capsules. 
     

  • Lupin completes Gavis acquisition
    MUMBAI and BALTIMORE — Lupin announced Wednesday that it had completed its acquisition of Gavis, which includes Gavis Pharmaceuticals and Novel Laboratories, for about $880 million. 
     
    Lupin said the acquisition will grow the company’s footprint in the U.S. generics market and expands its dermatology, controlled substance product and high value and niche generics pipeline. With the acquisition, Lupin also gains its first manufacturing site in the United States — Gavis’ New Jersey manufacturing facility. 

  • CMS plan to boost MTM gains traction in Congress

    “Better care, smarter spending, healthier people.”

  • TherapeuticsMD launches Rx prenatal that's certified vegan and certified kosher
    BOCA RATON, Fla. - TherapeuticsMD recently announced the launch of vitaMedMD's newest prescription prenatal multivitamin, vitaTrue, adding to its prenatal line consisting of vitaPearl, vitaMedMD One Rx, vitaMedMD Plus Rx and vitaMedMD RediChew Rx. 
     

  • CVS Health to offer naloxone without prescription in 23 states by month's end
    WOONSOCKET, R.I. - CVS Health announced Monday that it will expand access to the opioid overdose-reversal medication naloxone at the end of March at its CVS Pharmacy locations in eight new states, including: Connecticut, Kentucky, Maryland, North Carolina, New Hampshire, Ohio, Virginia and Vermont.  
     
    Under a physician-approved protocol permitted by the state, CVS Pharmacy will be able to dispense naloxone to patients in these states without the need for an individual prescription.
     
X
This ad will auto-close in 10 seconds